Next 10 |
home / stock / abbv / abbv articles
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net...
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants&nb...
Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Pha...
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...
On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE:ABB...
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. C...
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and ...
Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulation...
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a pot...
News, Short Squeeze, Breakout and More Instantly...
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net...
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants&nb...
2024-04-26 08:17:26 ET Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie’s earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 per share, in Q1 of FY23. The company’s ...